Company Overview and News


Add GWPRF
to your dashboard

Headline News

Zynerba Pharmaceuticals: 2 Pivotal Programs To Be Launched In 2018 Plus Upside In Epilepsy

2017-11-26 seekingalpha
Shares have risen by 50% in just a month since I suggested readers follow insiders back into the stock. (32-0)

A Current Look At The ROTY Contenders List

2017-11-25 seekingalpha
Today, we focus on the Contenders List, our constantly changing "bank" of ideas that are either setting up now or could offer an entry point later on. (325-3)

Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?

2017-11-23 seekingalpha
Shares have risen by 75% since bringing this stock to the attention of readers three weeks ago. (388-4)

GW Pharmaceuticals: Bull Thesis Strengthened And Further Upside Expected

2017-11-22 seekingalpha
Shares have risen substantially since I suggested that readers buy the dip. I believe additional upside in 2018 is probable. (68-0)

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update

2017-11-21 seekingalpha
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59. (1331-7)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-13)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-2)

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-11)

7 Marijuana Stocks to Buy That Won’t Burn You

2017-11-10 investorplace
Marijuana stocks have become a big deal in both the U.S. and Canada as investors, producers and all the others stakeholders involved try to capture their little piece of what’s sure to become a massive industry. (29-2)

Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts

2017-11-01 zacks
Major biotech companies reported earnings results over the last five trading days. While companies like Amgen (AMGN - Free Report) and Vertex (VRTX - Free Report) topped expectations, it was a mixed quarter for companies like Celgene (CELG - Free Report) , Alexion (Read more: Alexion Tops Q3 Earnings, Lags Sales, 2017 View Up) and BioMarin (Read more: BioMarin Q3 Loss Narrows, Profit Guidance Raised). (274-0)

Your Daily Pharma Scoop: Portola's PDUFA, PDLI Makes Some Money, GWPH Completes Rolling NDA

2017-10-31 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (765-3)

Can Pharma Succeed In A Condition Impacting 1 In 68 Children?

2017-10-31 seekingalpha
The pharmaceutical industry has struggled to address autism due to its heterogeneity, with only two medications approved for any autism symptom - both of which were blockbusters. (104-5)

NetworkNewsWire Announces Publication on the Impact of Biosynthesis on Cannabinoid Pharmaceuticals

2017-10-25 marketwired
NEW YORK, NY--(Marketwired - Oct 25, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. (38-0)

4 Medical Product Stocks Likely to Top Q3 Earnings Estimates

2017-10-18 zacks
The political gridlock over the pullback of the Affordable Care Act or Obamacare has been making headlines in the MedTech space. The MedTech space received a sudden jolt recently when White House pulled the plug on Obamacare subsidies that reduce health care costs for Americans with low incomes. There are concerns that the final ‘Trump-care plan’ will still include the MedTech tax repeal in its agenda. (15-0)

Intec Pharma: Buy The Dip

2017-10-15 seekingalpha
Parkinson's disease is a very attractive market opportunity, recent picks in the space have done well, and the company remains well positioned to capitalize. (21-1)